These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 28485390)

  • 1. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
    Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Albersen M; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Moris L; Battaglia A; van der Poel H; Walz J; Bossi A; De Meerleer G; Haustermans K; Van Poppel H; Spahn M; Joniau S
    Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):407-412. PubMed ID: 28485390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
    Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
    Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
    Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
    Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].
    Tabata K; Satoh T; Matsumoto K; Fujita T; Irie A; Iwamura M; Yanagisawa N; Matsuda D; Muramoto M; Kadowaki K; Suyama K; Shoji K; Koh H; Kawakami T; Okayasu I; Egawa S; Baba S
    Nihon Hinyokika Gakkai Zasshi; 2006 Jul; 97(5):712-8. PubMed ID: 16898594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
    Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
    Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
    Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
    Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
    Miyata Y; Nakamura Y; Yasuda T; Matsuo T; Ohba K; Furusato B; Fukuoka J; Sakai H
    Prostate; 2017 Oct; 77(14):1408-1415. PubMed ID: 28845514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy.
    Stewart SB; Cheville JC; Sebo TJ; Frank I; Boorjian SA; Thompson RH; Gettman MT; Tollefson MK; Umbriet EC; Psutka SP; Bergstralh EJ; Rangel L; Karnes RJ
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):332-7. PubMed ID: 25156060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
    Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
    BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy.
    Pu XY; Wang XH; Wu YL; Wang HP
    J Cancer Res Clin Oncol; 2007 Aug; 133(8):555-62. PubMed ID: 17457611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis.
    Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Albersen M; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Van Der Poel H; Walz J; De Meerleer G; Bossi A; Haustermans K; Van Poppel H; Spahn M; Joniau S;
    Eur Urol Focus; 2018 Apr; 4(3):369-375. PubMed ID: 28753838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
    Debruyne FM; Witjes WP
    Mol Urol; 2000; 4(3):251-6;discussion 257. PubMed ID: 11062381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of risk factors for positive surgical margin after laparoscopic radical prostatectomy with and without neoadjuvant hormonal therapy.
    Wang F; Zhang G; Tang Y; Wang Y; Li J; Xing N
    Front Endocrinol (Lausanne); 2023; 14():1270594. PubMed ID: 37941905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis.
    Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Aoki M; Takai Y
    World J Surg Oncol; 2014 Apr; 12():134. PubMed ID: 24885947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating prostate-specific antigen mRNA during radical prostatectomy in patients with localized prostate cancer: with special reference to neoadjuvant hormonal therapy.
    Ogawa O; Iinuma M; Sato K; Sasaki R; Shimoda N; Satoh S; Kato T
    Urol Res; 1999 Aug; 27(4):291-6. PubMed ID: 10460902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
    Noguchi M; Noda S; Nakashima O; Kojiro M
    Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.